Document:

exv10w43

 

EXHIBIT 10.43

Motorola Long Range Incentive Plan (LRIP) of 2005

ELIGIBILITY

Corporate, Senior and Executive Vice Presidents and other officers of Motorola, Inc. (“Motorola”)
or a Subsidiary, as recommended by the Chief Executive Officer and approved by the Compensation and
Leadership Committee of the Board of Directors (“Committee”), are eligible to participate in the
Motorola Long Range Incentive Plan (LRIP) of 2005 (the “Plan”). The Chief Executive Officer and the
Chief Operating Officer (if any) are also eligible to participate as approved by the Committee.

PARTICIPATION

Generally, officers who become eligible to participate during the first quarter of a performance
cycle will participate in a full multi-year performance cycle. The participation of officers who
are promoted, newly hired or demoted after the first quarter of a performance cycle shall be at the
discretion of the Chief Executive Officer.

OVERVIEW

The Plan is being implemented pursuant to the terms and conditions of the Omnibus Incentive Plan of
2003 (“Omnibus Plan”). Here is an overview of the Plan:

	»   	Performance Cycle
	 
	   	The Plan is based upon multi-year performance cycles selected by the Committee with an
initial three-year performance cycle beginning on January 1, 2005.

	»   	Performance Measures
	 
	   	Performance measures for each cycle will be determined by the Committee based on
improvement in economic profit and growth in sales of Motorola during each multi-year
performance cycle. Performance measures may apply to performance in each year in the
performance cycle, to cumulative performance during the entire performance cycle, or a
combination of both. If performance measures are applied to performance in each year in the
performance cycle, performance to target for each year shall be divided by the number of years
in the performance cycle and added together to determine the award for the entire performance
cycle. Awards may be subject to partial forfeiture if Motorola’s total shareholder return for
the entire performance cycle does not meet or exceed the median total shareholder return for the
performance cycle for a defined comparator group.
	 
	   	Economic profit is defined as net operating profit after tax minus a capital charge.
	 
	   	Net operating profit after tax and sales for each year during a performance cycle shall be
determined in accordance with generally accepted accounting principles but shall exclude the
effect of all acquisitions with a purchase price of $250 million or more, all gains or losses on
the sale of a business, any asset impairment equal to $100 million or more, and any other
special items designated by the Committee.

 

 

	»   	Maximum Earned Award
	 
	   	A participant’s maximum earned award will be two times his/her target award. A
participant’s target award is established at the commencement of a performance cycle based on a
percentage of the participant’s base pay rate in effect at that time.
	 
	»   	The Payout Process

	 	•  	All earned awards will be paid in stock.
	 
	 	•  	The number of shares of stock earned by a participant shall be determined by
dividing the amount of the award earned during the performance cycle by the closing
price of one share of Motorola common stock on the New York Stock Exchange on the
day before the date on which the Committee certifies the amount of the award earned
(the “Certification Date Value”).
	 
	 	•  	The Company shall have the right to satisfy all federal, state and local
withholding tax requirements with respect to the award earned by reducing the
number of earned shares by the number of shares determined by dividing the amount
of withholding required by the Certification Date Value.
	 
	 	•  	Payments will be made as soon as administratively practicable following the
close of a performance cycle. A participant has no right to any award until that
award is paid.
	 
	 	•  	If the Committee determines, in its sole discretion, that a participant has
willfully engaged in any activity at any time, prior to the payment of an award,
that the Committee determines was, is, or will be harmful to the Company, the
participant will forfeit any unpaid award.

SITUATIONS AFFECTING THE PLAN

	»   	Change in Employment

	 	•  	Generally, a participant will be eligible for payment of an earned award
only if employment as a Corporate, Senior or Executive Vice President continues
through the last day of the performance cycle.
	 
	 	•  	Pro rata awards may be possible, however, depending upon the type of employment
termination. The table below summarizes how earned awards will generally be
prorated in accordance with the type of employment termination:

-2-

 

	 	 	 
	 
	If employment terminates due to...	 	The earned award will be...
	 
	Death

	 	Pro rated based on the number
of completed months of
employment within the
performance cycle.
	 
	 	 
	Total and Permanent Disability

	 	Pro rated based on the number
of completed months of
employment within the
performance cycle.
	 
	 	 
	Retirement

	 	Pro rated based on the number
of completed months of
employment within the
performance cycle.
	 
	 	 
	Termination of Employment Because of
Serious Misconduct

	 	Forfeited.
	 
	 	 
	Change in Employment in Connection with a

Divestiture

	 	Forfeited.
	 
	 	 
	Termination of Employment for any Other
Reason than Described Above

	 	Forfeited.
	 
	 	 
	For purposes of determining a prorated payout, completed months of employment will include only those

	months in which the participant is actually working and is a Corporate, Senior or Executive

	Vice President

	 

	 	•  	In the event a participant remains on payroll as an active employee at the
end of a performance cycle, but is not actually working and is not on a leave of
absence at that time, the participant will be entitled to a pro rata award based on
the number of completed months of employment within the performance cycle in which
the participant was actually working and is a Corporate, Senior or Executive Vice
President, provided that the participant is otherwise eligible for an award. A
participant who remains on payroll as an active employee at the end of a
performance cycle, but is not actually working and is on a leave of absence which
carries a right to return to work, will be entitled to a full award for the
performance period, provided the participant actually worked for some portion of
the performance cycle.
	 
	 	•  	A prorated payout will be based on final performance results and paid as soon as
administratively practicable after the end of a performance cycle.
	 
	 	   	For purposes of the Plan, “Total and Permanent Disability” and Retirement” will be defined
as set forth below:
	 
	 	•  	Total and Permanent Disability means for (x) U.S. employees, entitlement to
long-term disability benefits under the Motorola Disability Income Plan, as amended
and any successor plan and (y) non-U.S. employees, as established by applicable
Motorola policy or as required by local regulations.

-3-

 

	 	•  	Retirement means retirement from Motorola or a Subsidiary as follows:

(i) Retiring at or after age 55 with 20 years of service;

(ii) Retiring at or after age 60 with 10 years of service;

(iii) Retiring at or after age 65, without regard to years of service;

(iv) Retiring with any other combination of age and service, at the discretion of
the Committee.

Years of service will be based on the participant’s Service Club Date.

	»   	Change in Control
	 
	   	If Motorola undergoes a Change in Control as defined in the Omnibus Plan:

	 	•  	If performance measures are applied to performance in the entire performance
cycle, the sales growth and economic profit improvement for the performance cycle
will be determined as of the effective date of the Change in Control and pro rata
award payments will be made based on the number of completed months of the cycle as
of the effective date of the Change in Control.
	 
	 	•  	If performance measures are applied to performance in each year in the
performance cycle, the sales growth and economic profit improvement for any partial
year will be determined as of the date of the Change in Control and performance to
target as of that date will be divided by the number of years in the performance
cycle and added to the amounts earned in any completed years.
	 
	 	•  	Awards will not be subject to any partial forfeiture based on total shareholder
return.
	 
	 	•  	Awards will be paid in stock as soon as administratively practicable following
the effective date of the Change in Control, but no later than 90 days after that
date.

DEFINITION OF TERMS

“Subsidiary” means an entity of which Motorola owns directly or indirectly at least 50% and that
Motorola consolidates for financial reporting purposes.

“Serious Misconduct” means any misconduct that is a ground for termination under the Motorola Code
of Business Conduct, or human resources policies, or other written policies or procedures.

If a term is used but not defined, it has the meaning given such term in the Omnibus Plan.

-4-

 

RESERVATION AND RETENTION OF COMPANY RIGHTS

	 	•  	The selection of any employee for participation in the Plan will not give
that participant any right to be retained in the employ of the Company.
	 
	 	•  	Participation in the Plan is completely at the discretion of Motorola, and
Motorola’s decision to make an award in no way implies that similar awards may be
granted in the future.
	 
	 	•  	Anyone claiming a benefit under the Plan will not have any right to or interest
in any awards unless and until all terms, conditions, and provisions of Plan that
affect that person have been fulfilled as specified herein.
	 
	 	•  	No employee will at any time have a right to be selected for participation in a
future performance period for any fiscal year, despite having been selected for
participation in a previous performance period.

GOVERNANCE

It is expressly understood that the Committee is authorized to administer, construe, and make all
determinations necessary or appropriate to the administration of the Plan, all of which will be
binding upon the participant.

AMENDMENT, MODIFICATION, and TERMINATION

The Committee may amend, modify, or terminate the Plan and the terms applicable to any performance
cycle at any time; provided, however, that no such action may adversely affect a participant’s
rights under the Plan subsequent to such time as negotiations or discussions which ultimately lead
to a Change in Control have commenced.

MISCELLANEOUS PROVISIONS

	 	•  	Award opportunities may not be sold, transferred, pledged, assigned, or
otherwise alienated or hypothecated, other than by will or by the laws of descent
and distribution.
	 
	 	•  	To the extent permitted by law, amounts paid under the Plan will not be
considered to be compensation for purposes of any benefit plan or program
maintained by the Company.
	 
	 	•  	All obligations of the Company under the Plan with respect to payout of awards,
and the corresponding rights granted thereunder, will be binding on any successor
to the Company, whether the existence of such successor is the result of a direct
or indirect purchase, merger, consolidation, or other acquisition of all or
substantially all of the business and/or assets of the Company.
	 
	 	•  	In the event that any provision of the Plan will be held illegal or invalid for
any reason, the illegality or invalidity will not affect the remaining parts of the
plan, and the Plan will be construed and enforced as if the illegal or invalid provision
had not been included.

-5-

 

	 	•  	No participant or beneficiary will have any interest whatsoever in any specific
asset of the Company. To the extent that any person acquires a right to receive
payments under the Plan, such right will be no greater than the right of any
unsecured general creditor of the Company.
	 
	 	•  	To the extent not preempted by federal law, the Plan, and all agreements
hereunder, will be construed in accordance with and governed by the laws of the
state of Illinois without giving effect to the principles of conflicts of laws.
	 
	 	•  	This Plan constitutes a legal document which governs all matters involved with
its interpretation and administration and supersedes any writing or representation
inconsistent with its terms.

-6-<PAGE>
                                                                    EXHIBIT 10.1

Confidential treatment has been requested for portions of this Exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated by ***. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.

                        DISTRIBUTION AND SUPPLY AGREEMENT

                                     BETWEEN

                         SPECTRUM PHARMACEUTICALS, INC.

                                       AND

                          CURA PHARMACEUTICAL CO. INC.

<PAGE>

      DISTRIBUTION AND SUPPLY AGREEMENT (this "Agreement") made as of the 13th
day of April, 2005 between SPECTRUM PHARMACEUTICALS, INC., a Delaware
corporation with its principal offices at 157 Technology Drive, Irvine,
California, USA, 92618 (hereinafter called "SPECTRUM") and CURA PHARMACEUTICAL
CO., INC., a New Jersey corporation with its principal offices at 542 Industrial
Way West, Eatontown, New Jersey, USA, 07724 (hereinafter called "CURA").

      Defined terms used in this Agreement shall have the meanings set forth in
Section 1 hereof, except as otherwise provided herein.

      WHEREAS, SPECTRUM is engaged in the licensing, development and
      commercialization of pharmaceutical products and wishes to market a
      certain product in the Territory.

      WHEREAS, CURA is a distributor and seller of pharmaceutical products in
      the Territory and desires to obtain an exclusive right to, distribute,
      promote and sell the product supplied by SPECTRUM in the Territory;

      WHEREAS, SPECTRUM has agreed, subject to the terms and conditions of the
      Agreement, to grant CURA the exclusive right to distribute the Product in
      the Territory and to supply to CURA on an exclusive basis in the Territory
      all of CURA's requirements of the Product;

      WHEREAS, CURA has agreed, subject to the terms and conditions of the
      Agreement, to grant SPECTRUM the exclusive right to supply the Product to
      CURA for the Territory and to undertake the distribution of such Product
      in the Territory; and

      WHEREAS, in connection with the foregoing, CURA and SPECTRUM have agreed
      to implement a profit-sharing arrangement in respect of the sale and
      distribution by CURA of the Product in the Territory.

      NOW, THEREFORE, the parties agree as follows:

1. DEFINITIONS.

      For the purposes of this Agreement the following terms have the following
      meanings:

      1.1   "AFFILIATES" shall mean (a) an entity controlled by a common parent
            that owns more than fifty percent of the voting stock of both such
            entity and one of the parties to this Agreement and (b) such parent
            company.

      1.2   "ANDA'S" shall mean the Abbreviated New Drug Applications filed with
            the FDA in connection with the Products.

                                       2
<PAGE>

      1.3   "APPROVED PRODUCT" shall mean any Product that shall have been
            granted all necessary approvals by all required Regulatory
            Authorities to allow the sale and distribution by CURA or an
            Affiliate of CURA of such Product in the Territory.

      1.4   "BATCH", with respect to any of the Products, shall mean a separate
            and distinct quantity of such Product processed under continuous and
            identical conditions and designated by a batch number.

      1.5   "CERTIFICATE OF ANALYSIS" shall mean a document, which is dated and
            signed by a duly authorized representative of the Quality Control or
            Quality Assurance Department of SPECTRUM, certifying that a Batch of
            any Product meets all Specifications.

      1.6   "FDA" shall mean the U.S. Food and Drug Administration, or any
            successor body.

      1.7   "FD&C ACT" means the Federal Food, drug and Cosmetic Act of 1938, as
            amended and the regulations thereunder, as the same may be amended
            or revised.

      1.8   "FIRST APPROVAL DATE" shall mean the date on which CURA or SPECTRUM
            first obtains approval from a Regulatory Authority in the Territory
            to market a Product.

      1.9   "FISCAL YEAR" shall mean the twelve-month period commencing on
            January 1st of each year and ending on December 31st, or any other
            twelve-month period designated as the fiscal year of CURA.

      1.10  "CGMP" shall mean current good manufacturing practices as required
            by the rules and regulations of the applicable Regulatory Authority.

      1.11  "INDEPENDENT LABORATORY" shall have the meaning set forth in Section
            8.4 hereof.

      1.12  "LAUNCH DATE", as to each Approved Product, shall mean that date on
            which marketing and distribution of such Approved Product shall
            commence in the Territory.

      1.13  "LAUNCH NOTICE" shall have the meaning set forth in Section 6.1
            hereof.

      1.14  "LIAISON COMMITTEE" shall have the meaning set forth in Section 3
            hereof.

                                       3
<PAGE>

      1.15  "MANUFACTURING COST" with respect to the Product shall mean [***].
            Current actual costs that shall remain in effect for the first year
            of this contract are set forth on Schedule B.

      1.16  "MANUFACTURING PARTNER" shall mean a pharmaceutical manufacturer
            selected and contracted by SPECTRUM to manufacture the Product
            according to SPECTRUM'S specifications.

      1.17  "NET PROFITS" with respect to each of the Products shall mean the
            Net Sales made by CURA of such Product less SPECTRUM's Manufacturing
            Costs in respect of such Product.

      1.18  "NET SALES" in respect the Product shall mean CURA's gross invoice
            amounts on such sales of such Product by CURA and/or its Affiliates
            to third parties, less the following deductions reasonably and
            properly incurred in the ordinary course of business and paid or
            given:

            (a)   transportation cost to deliver Product from CURA to its
                  customer;

            (b)   trade, quantity or cash discounts, service allowances and
                  independent brokers or agents' commissions, off-invoice
                  promotional discounts, rebates, volume reimbursements, if any,
                  given, allowed or paid, such amounts to be agreed to by the
                  parties prior to being given, allowed or paid by CURA;

            (c)   credits or allowance for such Product, if any, given or made
                  on account of price and shelf adjustments, returns, bad debts,
                  charge backs, any and all federal, state or local government
                  rebates or discounts whether in existence now or enacted at
                  any time hereafter, and the gross amount bill for that
                  rejected Product or such Product recalled, seized or destroyed
                  (voluntarily (to be mutually agreed to by both parties) or at
                  the request of any government agency, subdivision or
                  department);

            (d)   any tax, excise or other government charge upon or measured by
                  the production, sale, transportation, delivery or use of such
                  Product; and any surcharge, levy, tax or assessment mandated
                  by any federal, state or local government or administrative
                  agency to fund a compensation program or reserve for persons
                  injured by such Product; in each case determined in accordance
                  with CURA's customary accounting policies and practices in a
                  manner consistent with Generally Accepted Accounting
                  Principles in the United States.

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       4
<PAGE>

      1.19  "OBJECTION NOTICE" shall have the meaning set forth in Section 8.4
            hereof.

      1.20  "PRODUCT" shall mean the product set forth on Schedule A.

      1.21  "REGISTRATION" with respect to the Product means the meeting of all
            of the requirements of all applicable Regulatory Authorities
            necessary to permit the commencement of manufacturing and marketing
            of such Product in the Territory by CURA or an Affiliate of CURA.

      1.22  "REGULATORY AUTHORITY" means any and all bodies and organizations
            regulating the manufacture, importation, distribution, use and sale
            of any of the Products in the Territory.

      1.23  "SPECTRUM'S FACILITY" shall mean the facility or the facilities that
            SPECTRUM shall contract to have the Product manufactured in for sale
            to CURA.

      1.24  "SPECIFICATIONS" of Product means the specifications for any Product
            as agreed to by the parties and as approved by the applicable
            Regulatory Authority. The Specifications may be amended from time to
            time by written agreement between the parties and as specifically
            requested by applicable Regulatory Authorities.

      1.25  "TECHNICAL INFORMATION" shall mean the manufacturing process and any
            and all technical knowledge, trade secrets, analytical methodology,
            processes, manufacturing and toxicological information, and any and
            all other technical information or experience related to the
            manufacturing of any of the Products.

      1.26  "TERRITORY" shall mean the U.S.

      1.27  "U.S." means the United States of America and its territories and
            possessions.

2. APPOINTMENT OF CURA AS DISTRIBUTOR; SUB-DISTRIBUTORS

      2.1   SPECTRUM hereby grants to CURA and CURA hereby accepts, the
            exclusive right to distribute, promote and sell the Product in the
            Territory subject to the terms and conditions of this Agreement.
            CURA hereby grants to SPECTRUM and SPECTRUM accepts, the exclusive
            right to supply the Product to CURA for sale in the Territory
            subject to the terms and conditions of this Agreement.

                                       5
<PAGE>

      2.2   CURA shall use best efforts to promote, distribute and sell the
            Product in and throughout the Territory and shall use best efforts
            to maintain a reasonably adequate level of stock of such Product to
            meet the market demand for such Product within and throughout the
            Territory.

      2.3   CURA undertakes and agrees that it will not sell any of the Product
            directly or indirectly outside the Territory nor export any of the
            Product out of the Territory nor fill any orders for any of the
            Product knowing that such orders are intended for sale outside the
            Territory.

      2.4   Subject to the limitations set forth in the following sentence, CURA
            shall have the right to appoint any sub-distributor to distribute,
            market, promote and/or sell the Product within the Territory. The
            appointment of any sub-distributor shall be on such terms and
            conditions as CURA may reasonably require in writing provided such
            terms and conditions are not inconsistent with the terms and
            conditions of this Agreement. CURA agrees that it shall, at all
            times, be solely responsible for the acts, deeds or omissions of any
            sub-distributor appointed pursuant to this subsection 2.4.
            Notwithstanding the foregoing, (a) the appointment of a
            sub-distributor shall not in any way diminish, reduce or eliminate
            any of CURA's obligations under this Agreement, and CURA shall
            remain primarily liable for all such obligations; and (b) prior to
            entering into an agreement with a sub-distributor, CURA shall notify
            SPECTRUM of the proposed agreement, including the name of the
            proposed sub-distributor.

3. LIAISON COMMITTEE

            From time to time as reasonably agreed to by the parties, and at
            least once each calendar quarter from the date hereof, SPECTRUM and
            CURA shall meet and confer with each other concerning, among other
            things, the manufacture and marketing of the Product, the pricing of
            the Product and any deductions or allowances allowed or paid that
            affect Net Sales. SPECTRUM and CURA each shall be represented at
            such meetings by not more than three (3) representatives, who,
            collectively, shall constitute a "Liaison Committee."

4. MANUFACTURE AND SUPPLY OF THE PRODUCTS BY SPECTRUM

      4.1   SPECTRUM shall cause a Manufacturing Partner, to manufacture the
            Product to supply such Product to CURA, pursuant to the binding
            forecasts and purchase orders placed by CURA in accordance with
            Section 6 hereof, at SPECTRUM's current Manufacturing Cost of such
            Product as set forth on Schedule B for the first year of the
            contract and then, as provided in Section 7 hereof.

                                       6
<PAGE>

      4.2   Notwithstanding any other provision in this Agreement to the
            contrary:

            (a)   SPECTRUM shall have the option of terminating the supply of
                  the Product to CURA; and

            (b)   CURA shall have the option of discontinuing the marketing of
                  the Product in the Territory, at any time, in the event that,
                  in both parties reasonable judgment, the parties mutually
                  conclude, as the case may be, that continuing to market such
                  Product will be commercially unprofitable. In the event that
                  SPECTRUM elects to terminate the supply of the Product or CURA
                  elects discontinue the marketing of the Product, then such
                  party, upon [***] days written notice to the other party,
                  shall have no further liability to the other in respect
                  thereto other than remittance of respective share of profits
                  from continued sales of Product during this period or from
                  remaining inventory of Product which the parties may agree to
                  continue active selling after the [***] day period. In
                  addition, notwithstanding the above, CURA shall be obligated
                  to take delivery of and market (and may not return to
                  SPECTRUM) any amounts of Product included in the last binding
                  forecast provided to SPECTRUM prior to the election to
                  discontinue marketing the Product.

5. LABELING

      Subject to CURA's fulfillment of its obligations set forth in the
      immediately following sentence of this Section 5, SPECTRUM shall package
      and label the Approved Product in accordance with the specifications
      approved by the FDA in issuance of the ANDA. CURA shall supply trade dress
      and other necessary information requested by SPECTRUM that is required for
      labeling. SPECTRUM shall be fully responsible for the form and content of
      the Product label and other aspects of Product packaging and labeling,
      except to the extent of content supplied by CURA.

6. FORECASTS, ORDERS, DELIVERY AND PURCHASE OBLIGATIONS.

      6.1   When both parties agree that Registration of the Products is likely
            to be imminent, the parties shall meet and agree upon an estimated
            Launch Date in respect of such Approved Product. Thereafter, CURA
            shall send to SPECTRUM a notice (the "Launch Notice") with respect
            to such Product that shall contain the following:

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       7
<PAGE>

            (a)   a statement of the estimated Launch Date of such Product; and;

            (b)   a purchase order for such Product to be purchased by CURA,
                  prior to the Launch Date, in respect of such Product.

      6.2   On the first day of each calendar quarter commencing after the
            Launch Date of each Approved Product, CURA shall provide to SPECTRUM
            a forecast of the amount of such Product to be ordered for delivery
            during each of the [***] following the date of the forecast. The
            amounts forecasted for [***] in such forecast shall be a binding
            purchase obligation of CURA. CURA shall use best efforts to make the
            subsequent [***] in the forecast as accurate as possible.

      6.3   SPECTRUM shall not be required to supply during any particular
            Quarter more than [***] of the most recent forecasted amount for
            such quarter, but will use all reasonable efforts to supply the full
            amount ordered.

      6.4   CURA shall place a written purchase order with SPECTRUM for the
            quantity and the delivery date of the Product that it desires to
            purchase under this Agreement for commercial use; provided, however,
            that where in conflict with the terms and conditions of this
            Agreement, this Agreement, and not such standard terms and
            conditions set forth in the purchase orders, shall govern the
            purchase and sale of the Product under this Agreement. CURA agrees
            to place such purchase orders at least [***] days in advance of the
            specified delivery date, unless otherwise agreed to by the parties.
            Upon its receipt and acceptance of each such order, SPECTRUM shall
            use its best efforts to fulfil the order as requested. Unless
            SPECTRUM delivers a written objection to a purchase order within
            [***] of its receipt of such order, the purchase order shall be
            deemed accepted. The purchase orders placed by CURA must be
            consistent with the binding forecasts provided under Section 6.2
            above.

      6.5   SPECTRUM will retain title and risk of loss to all Product until
            delivered FOB ex SPECTRUM's Facility or such other place or places
            as may be mutually agreed by the parties. Thereafter, CURA will have
            the title and risk of loss of all Product.

      6.6   Both parties shall mutually agree on the price at which CURA shall
            sell the Approved Product in the Territory.

      6.7   Should SPECTRUM fail to supply product on an agreed upon delivery
            date, and CURA suffers financial loss due to SPECTRUM's or
            SPECTRUM'S Manufacturing Partner's failure to supply as a result of

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       8
<PAGE>

            sales contracts or other sales agreements that Cura has entered
            into, SPECTRUM will reimburse Cura for these financial losses.
            Reimbursement shall be in U.S. currency and shall be issued
            immediately upon Cura's supplying SPECTRUM with written proof of
            financial loss due to SPECTRUM's or SPECTRUM'S Manufacturing
            Partner's failure to supply product on specified delivery dates. As
            a condition to SPECTRUM's obligation under this Section 6.7, CURA
            shall use best efforts to try to avoid any financial loss by
            renegotiating the sales contracts or other sales agreements for new
            delivery dates.

7. PRICE AND PAYMENT

      7.1   CURA and SPECTRUM shall divide the Net Profits earned in connection
            with the sale and distribution of the Approved Product with [***]
            percent ([***]%) of the Net Profit to be distributed to SPECTRUM and
            [***] percent ([***]%) of the Net Profit to be distributed to CURA
            until SPECTRUM'S cumulative share of the net profit shall reach the
            total of [***] U.S. dollars. When SPECTRUM's cumulative share of the
            Net Profit reaches the [***] dollar milestone a new formula for the
            division of the Net Profit will be instituted so that SPECTRUM
            receives [***] percent ([***]%) of the Net Profit and CURA receives
            [***] percent ([***]%) of the Net Profit. SPECTRUM shall not be
            responsible for any share of any net loss should Manufacturing Costs
            exceed Net Sales.

      7.2   Starting in the second year of the contract when the current
            Manufacturing Cost set forth on Schedule B expires, not later than
            [***] days after the close of each [***], commencing with the first
            such [***] in the second year which Approved Product is delivered to
            CURA, SPECTRUM shall calculate its Manufacturing Costs and shall
            provide CURA with such calculations, including a statement setting
            forth in detail by category the amounts used to calculate
            Manufacturing Costs for such [***].

      7.3   Within [***] days from the close of each [***], commencing with the
            first such [***] in which funds are actually collected by CURA in
            respect of the commercial sale and distribution of the Approved
            Product, CURA shall submit to SPECTRUM a written statement (the
            "[***] Net Profit Statement") in the form set forth on Schedule C
            hereto, showing the share of Net Profits and Manufacturing Costs due
            to SPECTRUM, and shall deliver to SPECTRUM by wire transfer its
            share of the Net Profit amount shown as due and payable to SPECTRUM.
            Notwithstanding the foregoing, CURA shall deliver to SPECTRUM by
            wire transfer the Manufacturing Costs due SPECTRUM within [***] days
            after Product is delivered to CURA FOB ex SPECTRUM's factory. This
            amount is non-refundable. Along with that

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       9
<PAGE>

            first [***] Net Profit Statement for the [***] that funds were first
            collected, CURA shall provide the [***] Net Profit Statements and
            the corresponding payments for those [***] that passed before funds
            were collected.

      7.4   Not later than [***] days following the close of each Fiscal Year,
            CURA shall deliver a written statement (the "Final Net Profit
            Statement"), in the form set forth on Schedule D hereto.

      7.5   To the extent that, as a result of final adjustments reflected in an
            annual audit statement to be performed by an auditor chosen by
            SPECTRUM and reasonably acceptable to CURA, (a) CURA has underpaid
            to SPECTRUM its share of the Net Profits in respect of such Fiscal
            Year, then CURA, within [***] of delivering such annual audit
            statement to SPECTRUM, shall promptly pay to SPECTRUM by wire
            transfer the amount of such short-fall, or (b) CURA has overpaid to
            SPECTRUM its share of the Net Profits in respect of such Fiscal
            Year, then SPECTRUM, within [***] of CURA's delivery of such annual
            audit Statement to SPECTRUM shall pay to CURA by check, the amount
            of such over-payment. In addition, starting in the second year of
            the contract when the current Manufacturing Cost set forth on
            Schedule B expires, CURA shall have the right, once annually and at
            its own cost, during regular business hours, upon giving reasonable
            prior written notice to SPECTRUM to have an independent
            professionally qualified auditor, reasonably approved by SPECTRUM,
            audit SPECTRUM'S records relative to SPECTRUM'S calculation of the
            Manufacturing Costs.

      7.6   In the event that CURA sells any Product in combination with any
            other products, as a part of a package deal or combined deal, it
            agrees not to make any such deal on terms that would in any way
            disadvantage SPECTRUM or diminish its share of Net Profits under the
            terms of this Agreement. In addition, CURA shall not discount the
            price of the Product when it is sold or combined with another
            product.

      7.7   After the Final Net Profit Statement for a Fiscal Year has been
            audited and adjusted, if the aggregate amount that CURA received for
            its share of the Net Profit for such Fiscal Year is less than [***]
            of the Net Sales for such Fiscal Year, then the parties shall in
            good faith renegotiate the share of the Net Profit set forth in
            Section 7.1 for future Fiscal Years.

8. QUALITY CONTROL AND PRODUCT ACCEPTANCE.

      8.1   SPECTRUM shall ensure that all Products supplied to CURA under the
            terms of this Agreement will meet the Specifications.

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       10
<PAGE>

      8.2   SPECTRUM shall ensure that each Batch of Product is labeled and each
            of the Batch numbers is applied to each such Batch, as required by
            the applicable Regulatory Authority. SPECTRUM will ensure that a
            copy of the Certificate of Analysis with respect to each Batch of
            Product supplied to CURA (a) is faxed to CURA prior to shipping such
            Batch to CURA (confirmed by hard copies mailed to CURA) and (b)
            accompanies each Batch. SPECTRUM shall not ship any Batch of Product
            to CURA if such Batch does not meet the Specifications.

      8.3   SPECTRUM shall provide and maintain suitable storage and transport
            conditions for each Batch of Product and shall provide CURA with
            complete written instructions with respect to proper conditions for
            the transport and storage of Product. Upon receipt of any Batch of
            Product to CURA by SPECTRUM, CURA shall provide and maintain
            suitable storage conditions therefor and shall comply with any
            written instructions provided by SPECTRUM in respect of the
            transport and storage of Product.

      8.4   All shipments of Product received by CURA shall be deemed accepted
            unless CURA gives SPECTRUM a written Notice (the "Objection Notice")
            within [***] of such receipt specifying the manner in which the
            Batch of Product does not conform to Specifications. The Objection
            Notice shall be accompanied by written reports of any testing
            performed by or for CURA on such Batch. Upon receipt of the
            Objection Notice, SPECTRUM may request CURA to return the rejected
            Product or samples thereof for further testing. The test results, if
            any, submitted to SPECTRUM by CURA shall be deemed conclusive unless
            SPECTRUM notifies CURA within [***] of its receipt of the Objection
            Notice or the samples, whichever is later, that it disagrees with
            such test results. In the event of such notice by SPECTRUM, the
            rejected Product or samples thereof shall be submitted to a mutually
            acceptable independent laboratory (the "Independent Laboratory") for
            analysis in the form of a written report (the "Report"), the costs
            of which shall be paid by CURA except if the results of the Report
            determine that any of the Product rejected by CURA does not meet the
            applicable Specifications, in which case SPECTRUM will pay for all
            such costs. If the Report states that the Product meets the
            Specifications, CURA must pay SPECTRUM the Manufacturing Costs for
            the Product and use its best efforts to sell the Product. SPECTRUM
            will use its best efforts to replace Product that does not meet the
            applicable Specifications with conforming goods as soon as
            reasonably possible, provided that the departure from Specifications
            is not due to the fault or act of CURA. All transportation, shipping
            and insurance costs and other fees incident to the shipping back to
            SPECTRUM of the Product determined by the Report not

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       11
<PAGE>

            to meet Specifications and the shipping to CURA of the replacement
            Product will be paid for by SPECTRUM. In the event that replacement
            Product is required, it shall be shipped via airfreight unless
            otherwise agreed to in writing by CURA. Once the Product is deemed
            accepted by CURA or the Report states that the Product meets the
            Specifications, CURA shall be obligated to take the Product and pay
            SPECTRUM the Manufacturing Costs for the Product. Subject to Section
            8.1, CURA shall not be able to return the Product to SPECTRUM for
            any reason, nor shall CURA be entitled to any credits from SPECTRUM
            for any Product for any reason including but not limited to that it
            is not able to sell the Product or the Product is returned to it.

9. RECORDS AND INSPECTIONS.

      9.1   SPECTRUM will maintain records and documents documenting the
            Manufacturing Cost of each of the Product and CURA will maintain
            records and documents (including but not limited to information
            related to all allowances and deductions included under Section
            1.18) documenting all transactions relating to the sale of the
            Product for a time period equal to the greater of:

            (a)   the period meeting all known regulations of the applicable
                  Regulatory Authorities for periods with respect to such
                  Product; and

            (b)   five (5) years from the date of sale.

            Each of the parties will use commercially reasonable efforts to
            ascertain the retention requirements of the applicable Regulatory
            Authorities and will keep the other party informed of any changes
            that it becomes aware of that may reasonably affect such other
            party's obligations under this Section 9.1.

      9.2   Each party shall within forty-eight (48) hours notify the other
            party of any (a) inspections by any Regulatory Authority, including,
            without limitation, inspections as a result of the recall of, or any
            other regulatory issue related to any of the Product and/or (b)
            material notices received from any Regulatory Authority. Each party
            shall also have the duty immediately to notify the other if it
            becomes aware, or reasonably should have become aware, of any
            concern with respect to any Product that may affect the efficacy or
            safety of any of the Products.

                                       12
<PAGE>

10. INTELLECTUAL PROPERTY RIGHTS

      10.1  CURA acknowledges and agrees that SPECTRUM is the owner of the
            Technical Information, and of all industrial and intellectual
            property rights of any kind in relation to the Technical
            Information, including the right to patents, registered or other
            designs, copyright, trademarks or trade names and any other
            confidential information. In addition, CURA acknowledges and agrees
            that SPECTRUM is the owner of the ANDA. Nothing contained in this
            Agreement shall be effective to give CURA any rights of ownership in
            and to the Technical Information, the intellectual property and/or
            the ANDA owned by SPECTRUM.

      10.2  Any improvements to the Technical Information made or discovered by
            SPECTRUM during the term of this Agreement shall remain the property
            of SPECTRUM and all industrial and intellectual property rights of
            any kind in relation to such improvements, including the right to
            patents, registered or other designs, copyright, trademarks or trade
            names and any other confidential information, shall remain the
            property of SPECTRUM.

11. RELATIONSHIP OF SPECTRUM AND CURA.

      11.1  The relationship between SPECTRUM and CURA that is created by this
            Agreement shall be that of vendor and purchaser, and not that of a
            partnership, principal and agent, or joint or co-ventures. In the
            performance of this Agreement, CURA shall have no authority to
            assume or create any obligation or responsibility, either expressed
            or implied, on behalf of or in the name of SPECTRUM, or to bind
            SPECTRUM, its Affiliates or its Manufacturing Partners in any manner
            whatsoever and SPECTRUM shall have no authority to assume or create
            any obligation or responsibility, either express or implied, on
            behalf of or in the name of CURA or to bind CURA or its Affiliates
            in any manner whatsoever. Each party shall indemnify the other party
            for any claim asserted by any third party that the acts of such
            party or any of its Affiliates or Manufacturing Partners created any
            obligation or responsibility of the other party other than as
            expressly set forth in this Section.

      11.2  If this Agreement is terminated for any reason, neither party shall
            thereafter use, or permit anyone else under its control to use, the
            other's name in the promotion of its business or the offer for sale
            of any goods and neither party shall package or label any goods in a
            manner that the other party hereto might reasonably consider to be
            imitative of any goods sold by such party.

                                       13
<PAGE>

12. WARRANTIES.

      12.1  CURA hereby represents and warrants to SPECTRUM that:

            (a)   it has the corporate authority to enter into this Agreement
                  and to perform its obligations hereunder;

            (b)   it is not aware of any legal, contractual or other
                  restriction, limitation or condition which might affect
                  adversely its ability to perform hereunder; and

            (c)   all Product shipped by CURA pursuant to this Agreement (i)
                  shall not be adulterated Product within the meaning of the
                  FD&C Act; (iv) shall not be a product which would violate any
                  section of the FD&C Act if introduced into interstate commerce
                  and (v) shall be stored and handled by CURA at all times in
                  the proper manner and suitable conditions for such Product.

      12.2  SPECTRUM hereby represents and warrants to CURA that:

            (a)   it has the corporate authority to enter into this Agreement
                  and to perform its obligations hereunder;

            (b)   it is not aware of any legal contractual or other restriction,
                  limitation or condition which might affect adversely its
                  ability to perform hereunder;

            (c)   the manufacture, importation, and sale to CURA of any Product
                  provided by SPECTRUM to CURA hereunder and the distribution
                  such Product shall not violate the patent or intellectual
                  property rights of any third party in the Territory; and

            (d)   all Product shipped to CURA pursuant to this Agreement (i)
                  shall be manufactured, packaged and labeled in conformance
                  with the applicable Specifications for such Product at the
                  time of shipment, (ii) shall be manufactured, packaged and
                  labeled in a plant which meets the requirements of the
                  applicable Regulatory Authority where the Product is to be
                  sold, including, without limitation, conformance with cGMP,
                  (iii) shall not be adulterated Product within the meaning of
                  the FD&C Act; (iv) shall not be a product which would violate
                  any section of the FD&C Act if introduced into interstate
                  commerce and (v) shall be stored and handled by SPECTRUM at
                  all times in the proper manner and suitable conditions for
                  such Product.

                                       14
<PAGE>

      12.3  Each party hereby represents and warrants and covenants to the other
            that such party is not debarred under the Generic Drug Enforcement
            Act of 1992 and it does not and will not use in any capacity the
            services of any person debarred under the Generic Drug Enforcement
            Act of 1992; neither such party, nor, to the best of its knowledge,
            any of its employees, agents or contractors, has engaged in any
            activity which could lead to it becoming debarred under the Generic
            Drug Enforcement Act of 1992.

13. INDEMNIFICATION.

      13.1  CURA agrees to indemnify SPECTRUM, its affiliates and its
            Manufacturing Partners against and holds SPECTRUM, its affiliates
            and its Manufacturing Partners harmless from, any and all loss
            (except consequential loss, such as, for example, loss of business
            or of profits), liability, damage, claim, cost and expense
            (including, without limitation, reasonable attorney's fees and
            liabilities for personal injury suffered by any person) arising from
            or in connection with any:

            (a)   breach of the warranties by CURA hereunder;

            (b)   other misrepresentation or breach of this Agreement by CURA,
                  its affiliates or its sub-distributors to the extent they are
                  performing the provision in question for CURA or upon CURA's
                  request;

            (c)   claim, express, implied or statutory made by CURA, its
                  Affiliates or its sub-distributors, (except to the extent that
                  such claim has been approved by the Regulatory Authority or
                  authorized by SPECTRUM) as to the efficacy or safety of any of
                  the Products or the use to be made by any purchaser of any of
                  the Products; or

            (d)   any other act or omission of CURA, its Affiliates or
                  sub-distributors in connection with the sale and distribution
                  of any of the Products.

      13.2  SPECTRUM hereby agrees to indemnify and hold CURA and CURA's
            Affiliates harmless from any and all loss (except consequential
            loss, such as, for example, loss of business or of profits),
            liability, damage, claim, cost and expense (including, without
            limitation, reasonable attorney's fees and liabilities for personal
            injury suffered by any person) arising from or in connection with
            any:

            (a)   breach of the warranties by SPECTRUM;

            (b)   other misrepresentation or breach of this Agreement by
                  SPECTRUM or any wrongful act or omission of SPECTRUM and its

                                       15
<PAGE>

                  Manufacturing Partner in connection with its contract
                  obligations hereunder;

            (c)   claim, express, implied or statutory made by SPECTRUM, its
                  Affiliates, (except to the extent that such claim has been
                  approved by the Regulatory Authority or authorized by CURA) as
                  to the efficacy or safety of any of the Products or the use to
                  be made by any purchaser of any of the Products;

            (d)   suit, claim or proceeding brought against CURA in the
                  Territory based on any claim that CURA's activities with
                  respect to any Product constitute an infringement of any
                  process patent or intellectual property rights of any third
                  party in the Territory; or

            (e)   any other act or omission of SPECTRUM, its Affiliates or
                  Manufacturing Partners in connection with the manufacture,
                  packaging, labeling and sale of Product to CURA or its
                  Affiliates.

      13.3  If CURA or any of its Affiliates or SPECTRUM, its Affiliates or any
            of its Manufacturing Partners (in each case an "Indemnified Party")
            receives any written claim which it believes is the subject of
            indemnity hereunder by SPECTRUM or CURA, as the case may be, (in
            each case as "Indemnifying Party"), the Indemnified Party shall, as
            soon as reasonably practicable after forming such belief, give
            notice thereof to the Indemnifying Party, including full particulars
            of such claim to the extent known to the Indemnified Party;
            provided, that the failure to give timely notice to the Indemnifying
            Party as contemplated hereby shall not release the Indemnifying
            Party from any liability to the Indemnified party. The Indemnifying
            Party shall have the right, by prompt notice to the Indemnified
            Party, to assume the defense of such claim with counsel reasonably
            satisfactory to the Indemnified Party, and at the cost of the
            Indemnifying Party. If the Indemnifying Party does not so assume the
            defense of such claim or, having done so, does not diligently pursue
            such defense, the Indemnified Party may assume such defense, with
            counsel of its choice, but for the account of the Indemnifying
            Party. If the Indemnifying Party so assumes such defense, the
            Indemnified Party may participate therein through counsel of its
            choice, but the cost of such counsel shall be for the account of the
            Indemnified Party.

      13.4  The party not assuming the defense of any such claim shall render
            all reasonable assistance to the party assuming such defense, and
            all out-of-pocket costs of such assistance shall be for the account
            of the Indemnifying Party.

      13.5  No such claims shall be settled other than by the party defending
            the same, and then only with the consent of the other party, which
            shall not be

                                       16

<PAGE>

            unreasonably withheld; provided, that the Indemnified Party shall
            have no obligation to consent to any settlement of any such claim
            which imposes on the Indemnified Party any liability or obligation
            which cannot be assumed and performed in full by the Indemnifying
            party.

14. COMPLIANCE WITH LAW.

      14.1  It shall be the responsibility of CURA and SPECTRUM, respectively,
            to follow all procedures and take all actions which are necessary or
            required for agreements of this type by the laws, treaties or
            regulations applicable in the country in which it is, respectively,
            manufacturing or selling Product or manufacturing or marketing any
            of the Products.

      14.2  It is further agreed that neither party shall be obligated to carry
            out or perform any or all of the terms of this Agreement as shall
            constitute a violation of any treaty, law, code or regulation of any
            governmental authority whether local, national or international. In
            any event, the other terms of this Agreement shall nevertheless
            continue and the parties shall use all reasonable efforts to
            re-negotiate and amend this Agreement so that the performance of
            this Agreement as so amended will not involve any such violation.

15. CONFIDENTIALITY.

      15.1  Any confidential information disclosed during the term of this
            Agreement shall be governed by that certain Mutual Confidentiality
            Agreement dated February 7, 2005, by and between the parties.

16. AUDITS.

      16.1  Once annually, CURA or its authorized representative shall have the
            right, at its own cost, to visit SPECTRUM's or SPECTRUM'S
            Manufacturing Partner's Facility during regular business hours
            provided CURA gives reasonable prior written notice to SPECTRUM.
            During any such visit, CURA's representatives shall have the right
            (a) to inspect the manufacturing facilities, (b) to inspect quality
            control procedures, (c) to audit any records and reports pertinent
            to the development, manufacturing, disposition or transport of any
            of the Products to ensure that SPECTRUM complies with all applicable
            regulations for the production of Product, including, without
            limitation, compliance with applicable CGMP. SPECTRUM, at its
            discretion, may accompany CURA on the visit.

                                       17
<PAGE>

      16.2  CURA shall assume all risk of loss and indemnify and hold the other
            party harmless from and against any and all loss, liability, damage,
            claim and expense including, but not limited to, reasonable
            attorneys' fees arising out of or resulting from such audits or
            inspections.

      16.3  In the event of an audit by any Regulatory Authority, SPECTRUM and
            CURA each shall supply the other with a copy of any report received
            from such Regulatory Authority and shall use its best efforts to
            provide such Regulatory Authority with a prompt, accurate and
            complete response to any deficiencies noted during the audit. Both
            parties agree that they shall use their best efforts to promptly
            address, and if necessary correct, any and all such deficiencies to
            the satisfaction of such Regulatory Authority.

17. TERM AND TERMINATION.

      17.1  This Agreement shall be for an initial term commencing as of the
            date of this Agreement and continuing until the second (2nd)
            anniversary of the First Approval Date. This Agreement shall be
            extended automatically for two additional terms of two (2) years
            each, unless either party gives written notice of its intent not to
            renew, such notice to be given not later than [***] prior to the
            expiration date of the current term thereof.

      17.2  This Agreement may be terminated by notice in writing by either
            party if the other party shall default in the performance of any of
            its other obligations under this Agreement and such default shall
            continue for a period of not less than [***] after written notice
            specifying such default shall have been given; provided, however,
            that if such default is not capable of being cured within such [***]
            period but the party in default initiates and diligently continues
            good faith efforts to cure such default, such [***] period shall be
            extended to [***]; or (c) by either party if the other party makes
            an arrangement with its creditors or goes into bankruptcy,
            receivership or liquidation, or if a receiver or a receiver and
            manager is appointed in respect of the whole or a major part of the
            property or business of the party in default.

      17.3  [***] after notice of termination has been given as herein provided,
            the right of CURA to place orders for Product with SPECTRUM shall
            cease.

      17.4  Immediately upon termination or expiration of this Agreement, CURA
            shall have the obligation, if requested by SPECTRUM, to accept and
            market any Product in transit or subject to an accepted purchase
            order or binding forecast at the time of giving of written notice of
            termination.

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       18
<PAGE>

18. FORCE MAJEURE.

      Neither party shall be liable or be in breach of any provision of this
      Agreement for any failure or delay on its part to perform any obligation
      where such failure or delay has been occasioned by any act of God, war,
      riot, fire, explosion, flood, sabotage, unavailability of fuel, accidents
      of navigation or breakdown or damage of vessels or other conveyances for
      air, land or sea, other impediments or hindrances to transportation,
      government intervention (other than that of duly-authorized Regulatory
      Authority), strikes or other labor disturbances or any other cause beyond
      the control of the parties.

19. INSURANCE

      SPECTRUM and CURA each shall maintain adequate product liability insurance
      to cover product liability claims against it, respectively, as
      manufacturer of the Products and distributor of the Products.

20. NOTICES.

      Notices provided under this Agreement to be given or served by either
      party on the other shall be given in writing and served personally or by
      prepaid registered airmail post or by express mail or by means of
      facsimile to the following respective addresses or to such other addresses
      as the parties may hereafter advise each other in writing. It being agreed
      and understood by the parties that any such notice shall be deemed given
      and served the day transmitted by facsimile or a date three (3) days after
      the date of express mail or mail by courier.

      TO:      SPECTRUM

               SPECTRUM PHARMACEUTICALS, INC.
               157 Technology Drive
               Irvine, CA 92618
               Attention: Rajesh C. Shrotriya MD, Chairman, CEO and President
               Fax: +(949) 788-6706

      TO:      CURA

               CURA Pharmaceutical Co.
               542 Industrial Way West
               Eatontown, New Jersey 07724
               Attention: Fabio Lanzieri, President
               Fax: +1(732) 982-8308

                                       19
<PAGE>

21. EXECUTION OF ALL NECESSARY ADDITIONAL DOCUMENTS.

      Each party agrees that it will forthwith upon the request of the other
      party execute and deliver all such instruments and agreements and will
      take all such other actions as the other party may reasonably request from
      time to time in order to effectuate the provision and purposes of this
      Agreement.

22. WAIVER.

      The failure of either of the parties to insist upon a strict performance
      of any other terms and provisions therein shall not be deemed a waiver of
      any subsequent breach of default in the terms or provisions of this
      Agreement.

23. ASSIGNMENT AND AMENDMENT.

      23.1  Other than an assignment by either party to any of its Affiliates,
            neither this Agreement nor any rights arising hereunder shall be
            assigned by one party without the prior written consent of the other
            and then only upon approval of the other party and acceptance of
            such assignment in written form approved by such party, which
            approval shall not be unreasonably withheld. In the event of an
            assignment by either party to it Affiliate as permitted hereunder,
            the assigning party shall not be released from its obligations
            hereunder and shall guarantee the full performance by such Affiliate
            of such obligations. Notwithstanding the above, either party may
            assign this Agreement to a successor in interest pursuant to a
            merger, acquisition or sale of all or substantially all of the
            assignor's assets. Subject to the limitations on assignment herein,
            this Agreement shall be binding upon and inure to the benefit of any
            successors in interest and permitted assigns of CURA and SPECTRUM.
            Any such successor or permitted assignee shall expressly assume in
            writing the performance of all terms and conditions of this
            Agreement.

      23.2  No amendment hereof shall be binding unless made in writing and
            signed by the parties hereto.

24. ENTIRE AGREEMENT.

      This Agreement and that certain Mutual Confidentiality Agreement dated
      February 7, 2005, by and between the parties incorporates the entire
      understanding of the parties and revokes and supersedes any and all

                                       20

<PAGE>

      agreements, contracts, understandings or arrangements that might have
      existed heretofore between the parties regarding the subject matter
      hereof.

25. GOVERNING LAW; LANGUAGE.

      25.1  This Agreement shall be construed in accordance with and governed by
            the internal laws of the State of New York, excluding such state's
            rules relating to conflicts of laws, and its form, execution,
            validity, construction and effect shall be determined in accordance
            with such internal laws.

      25.2  The parties hereto agree that this Agreement shall be in the English
            language.

26. SEVERABILITY.

      If any term or provision of this Agreement shall be held invalid or
      unenforceable, the remaining terms hereof shall not be affected, but shall
      be valid and enforced to the fullest extent permitted by law.

27. HEADINGS.

      The headings used in this Agreement are intended for guidance only and
      shall not be considered part of this written understanding between the
      parties hereto.

28. PUBLICITY

      Except as required by law or the rules of the principal stock exchange on
      which the party's stock is traded, no party shall originate any public
      statement, news release or other public announcement (oral or written),
      whether in the public press, stockholders' reports, at investors meetings
      or meetings with individual investors, or otherwise, relating to this
      Agreement or to any sublicense hereunder, or to the performance hereunder
      or any such agreements, including information related to price and sales
      amounts, or use a party's name for any purpose, including, without
      limitation, in connection with the advertising or sale of the Product,
      without the prior written approval of the other party, such consent not to
      be unreasonably withheld. The parties each agree to respond to each such
      request within five (5) business days of receipt of a request (unless a
      shorter period of time is necessary to comply with law). In the case of
      unintentional public disclosure concerning this Agreement, any Product or
      any other subject matter hereof, the disclosing party shall promptly
      inform the other party of such disclosure and the other party shall be
      entitled to make a public announcement regarding the subject matter of the
      disclosure. The other party

                                       21

<PAGE>

      shall notify the disclosing party of their intention to make such an
      announcement. Following a party's consent to or approval of the public
      disclosure of any information pursuant to this Section 28, both parties
      shall be entitled to make subsequent public announcements of such
      information without renewed compliance with this Section 28, unless the
      scope and/or duration of such consent or approval is expressly limited.
      Upon conclusion of this Agreement, the parties will publish a press
      release on their future cooperation.

IN WITNESS WHEREOF, this Agreement has been executed by the parties on the date
first above written.

                                            CURA PHARMACEUTICAL CO., INC.

                                            By: /s/ Fabio Lanzieri
                                                --------------------------------
                                                Fabio Lanzieri
                                                President

                                            SPECTRUM PHARMACEUTICALS, INC.

                                            By: /s/ Rajesh C. Shrotriya
                                                --------------------------------
                                                Rajesh C. Shrotriya, M.D.
                                                Chairman, CEO and President

                                       22
<PAGE>

                                   SCHEDULE A

                                   THE PRODUCT
                                   -----------

GENERIC NAME                BRAND NAME                  [***]
------------                ----------

Carboplatin                 Paraplatin                  [***]
  [***]                       [***]                     [***]
  [***]                       [***]                     [***]
  [***]                       [***]                     [***]

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       23
<PAGE>

                                   SCHEDULE B

                             NET MANUFACTURING COST
                             ----------------------

GENERIC NAME       BRAND NAME        [***]        MANUFACTURING COST
------------       ----------                     ------------------

Carboplatin        Paraplatin        [***]              [***]
   [***]             [***]           [***]              [***]
   [***]             [***]           [***]              [***]
   [***]             [***]           [***]              [***]

-------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       24
<PAGE>

                                   SCHEDULE C

                       FORM OF [***] NET PROFIT STATEMENT
                           [***] ENDED XXXXX XX, XXXX

GROSS INVOICED SALES                                            $        -
                                                                  =============

LESS:
        Chargebacks                                                      -
        Rebates/Allowances                                               -
        Bad Debts                                                        -
        Returns                                                          -
        Shelf Adjustments                                                -
        Cash Discounts                                                   -
        Freight Out                                                      -
        Other                                                            -

        Total Deductions                                                 -
                                                                  -------------

NET SALES                                                        $       -
                                                                  =============

LESS:  Manufacturing Costs of Products                                   -
                                                                  -------------

NET PROFITS                                                      $       -
                                                                  -------------

-------------------------------------------------------------------------------

CURA PORTION                                                    $        -
                                                                  =============

SPECTRUM
       NET PROFIT PORTION                                       $        -
       + MANUFACTURING COST                                     $        -
DUE SPECTRUM                                                    $        -
                                                                  =============

-------------------------------------------------------------------------------

--------
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                       25
<PAGE>

                                  CONFIDENTIAL

                       SCHEDULE D
                       FORM OF FINAL NET PROFIT STATEMENT
                       FISCAL YEAR ENDED DECEMBER 31, xxxx

<TABLE>
<CAPTION>
                                                                           TOTAL              ACTUAL
                                  QTR 1     QTR 2     QTR 3     QTR 4     REPORTED    ADJ.    ANNUAL
                                  -----     -----     -----     -----     --------    ----    ------
<S>                               <C>       <C>       <C>       <C>       <C>         <C>     <C>

GROSS INVOICED SALES              $ -       $ -       $ -       $ -       $ -         $ -     $ -
                                  ------------------------------------------------------------------
LESS:                               -         -         -         -         -           -       -
  Chargebacks                       -         -         -         -         -           -       -
  Rebates/Allowances                -         -         -         -         -           -       -
  Bad Debts                         -         -         -         -         -           -       -
  Returns                           -         -         -         -         -           -       -
  Shelf Adjustments                 -         -         -         -         -           -       -
  Cash discounts                    -         -         -         -         -           -       -
  Freight Out                       -         -         -         -         -           -       -
  Other                             -         -         -         -         -           -       -
                                  ------------------------------------------------------------------
  Total Deductions                  -         -         -         -         -           -       -
                                  ==================================================================
  NET SALES                       $ -       $ -       $ -       $ -       $ -         $ -     $ -
                                  ------------------------------------------------------------------

  Less: Manufacturing Costs
    of Products                     -         -         -         -         -           -       -
                                  ------------------------------------------------------------------
  NET PROFITS                     $ -       $ -       $ -       $ -       $ -         $ -     $ -
                                  ==================================================================

----------------------------------------------------------------------------------------------------

CURA PORTION                      $ -       $ -       $ -       $ -       $ -         $ -     $ -
AMOUNT DUE SPECTRUM               $ -       $ -       $ -       $ -       $ -         $ -     $ -

----------------------------------------------------------------------------------------------------
AMOUNT PAID TO SPECTRUM IN FISCAL YEAR ENDING 12/31                                   $ -
ADJUSTED AMOUNT THAT SHOULD HAVE BEEN PAID TO SPECTRUM IN TWELVE MONTHS
  ENDED DECEMBER 31, 200X                                                               -
                                                                                      -----
AMOUNT DUE FROM/(TO) SPECTRUM                                                         $ -
                                                                                      =====
----------------------------------------------------------------------------------------------------
                                  CONFIDENTIAL
</TABLE>

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]